Human Metapneumovirus Inhibits IFN-β Signaling by Downregulating Jak1 and Tyk2 Cellular Levels by Ren, Junping et al.
Human Metapneumovirus Inhibits IFN-b Signaling by
Downregulating Jak1 and Tyk2 Cellular Levels
Junping Ren
1, Deepthi Kolli
1, Tianshuang Liu
1, Renling Xu
1, Roberto P. Garofalo
1,2,3, Antonella
Casola
1,2,3*, Xiaoyong Bao
1*
1Department of Pediatrics, University of Texas Medical Branch, Galveston, Galveston, Texas, United States of America, 2Departments of Microbiology and Immunology,
University of Texas Medical Branch, Galveston, Galveston, Texas, United States of America, 3Sealy Center for Vaccine Development, University of Texas Medical Branch,
Galveston, Galveston, Texas, United States of America
Abstract
Human metapneumovirus (hMPV), a leading cause of respiratory tract infections in infants, inhibits type I interferon (IFN)
signaling by an unidentified mechanism. In this study, we showed that infection of airway epithelial cells with hMPV
decreased cellular level of Janus tyrosine kinase (Jak1) and tyrosine kinase 2 (Tyk2), due to enhanced proteosomal
degradation and reduced gene transcription. In addition, hMPV infection also reduced the surface expression of type I IFN
receptor (IFNAR). These inhibitory mechanisms are different from the ones employed by respiratory syncytial virus (RSV),
which does not affect Jak1, Tyk2 or IFNAR expression, but degrades downstream signal transducer and activator of
transcription proteins 2 (STAT2), although both viruses are pneumoviruses belonging to the Paramyxoviridae family. Our
study identifies a novel mechanism by which hMPV inhibits STAT1 and 2 activation, ultimately leading to viral evasion of
host IFN responses.
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Introduction
Human metapneumovirus (hMPV) is a recently identified RNA
virus belonging to the family of Paramyxoviridae, subfamily
Pneumovirinae, genus Metapneumovirus [1–3] Since its discovery,
hMPV has been recognized as a leading cause of lower respiratory
infection in infants and children worldwide, second only to
respiratory syncytial virus (RSV) [2,4–6]. Virtually all children
older than five years show serologic evidence of hMPV infection
[3]. The virus is also associated with hospitalization and disease
severity among elderly and immunocompromised patients with
respiratory tract infections [7,8].
Respiratory epithelial cells are the primary target of hMPV
infection. An important feature of the host response to viral
infections is the production of interferons (IFNs), a group of
cytokines that activate an array of cellular genes that are critical in
restricting viral replication and modulating adaptive immunity.
Type I IFNs (IFN-a and IFN-b) are the key mediators produced
by airway epithelial cells infected with paramyxoviruses [9–12],
including hMPV [13]. Secreted IFN-a/b bind to IFN-a/b
receptors (IFNAR) leading to dimerization of the two subunits,
IFNAR1 and IFNAR2. IFNAR1 and IFNAR2 then undergo
conformational changes resulting in the activation of the Janus
tyrosine kinase (Jak)/signal transducer and activator of transcrip-
tion protein (STAT) pathway. Tyrosine kinase 2 (Tyk2), a kinase
belonging to the Jak family, is constitutively bound to IFNAR1
[14]. Tyk2 phosphorylates IFNAR1 at tyrosine residue 466 (Y466)
and creates a docking site for STAT2 [15]. Subsequently, Tyk2
phosphorylates STAT2 at tyrosine 690 (Y690). Phosphorylation of
STAT2 Y690 creates a new docking site for the SH2 domain of
STAT1 [16,17], which is subsequently phosphorylated at Y701 by
IFNAR2 bound-Jak1 [18]. Phosphorylated STAT1 and STAT2
then dimerize and bind to IRF-9 [19]. This newly formed
heterotrimer, IFN-stimulated gene factor 3 (ISGF3), translocates
to the nucleus where it binds to IFN-stimulated response elements
(ISRE) to initiate transcription of the interferon-stimulated genes
(ISGs), leading to the establishment of an antiviral state within the
host cell.
Almost all mammalian viruses, including paramyxoviruses, have
developed strategies to avoid host immune responses by attacking
the IFN system, which include direct targeting of signaling
molecules belonging to the Jak/STAT signaling pathway, and
increasing the expression or activity of endogenous cellular key
regulators, such as suppressor of cytokine signaling (SOCS)
proteins, protein tyrosine phosphatases (PTPs) and protein
inhibitor of activated STATs (PIAS), to downregulate Jak/
STAT-dependent signaling [20–23]. We have previously demon-
strated that airway epithelial cells produce type I IFNs upon
hMPV infection [13]. Recently, hMPV has been shown to
antagonize IFN-a signaling through inhibition of STAT1
phosphorylation [24]. However, the mechanism leading to
impaired STAT1 phosphorylation by hMPV infection was not
identified. In this study, we describe a mechanism that contributes
to hMPV antagonism of type I IFN signal transduction in human
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associated with decreased cellular level of Jak1 and Tyk2, due to
enhanced proteosomal degradation and reduced gene expression,
as well as decreased surface expression of type I IFN receptor. Jak1
and Tyk2 degradation was viral-replication dependent, as
infection with UV-inactivated hMPV failed to affect Jak1 and
Tyk2 cellular levels. On the other hand, RSV, a close
Paramyxoviridae family member, disrupts type I IFN-mediated
signaling in airway epithelial cells through STAT2 degradation,
without affecting the transcription and expression of Jak1 and
Tyk2. Inhibition of Jak/STAT signaling by hMPV likely results in
modulation of host cellular antiviral genes, allowing evasion of the
airway defense response and the establishment of a productive
infection. Given our limited knowledge of hMPV-induced
pathophysiology of airway disease, a better understanding of the
interplay between the virus and host immune defenses will help in
designing new attenuated live vaccine candidates and in
developing new antiviral treatment strategies.
Results
hMPV-induced STAT-dependent gene transcription
requires Jak/STAT signaling
Type I IFNs are a family of cytokines that mediate host
resistance to virus infection by induction of ISGs via activated Jak/
STAT signaling pathway. To confirm ISG transcription by
hMPV-induced type I IFN, cells were transfected with a luciferase
reporter plasmid containing five copies of the ISRE site derived
from ISG54 gene promoter (pISRE-Luc), which binds transcrip-
tion factors belonging to the STAT family, followed by hMPV
infection. Cells were harvested at various times post-infection (p.i.)
to measure luciferase activity. Mock infection and IFN-b
treatment were used as negative and positive controls, respectively.
We found that infection of A549 cells with hMPV, at an MOI of
0.5, caused a significant increase in the luciferase activity,
compared to mock-treated cells, indicating that hMPV induces
transcription of ISRE-dependent genes. hMPV replication was
required for viral-induced ISRE-dependent gene transcription, as
UV-inactivated hMPV failed to induce significant luciferase
activity (Fig. 1A).
Jak1, Tyk2, STAT1, and STAT2 are essential signaling
molecules for IFN-a/b-induced ISRE-dependent gene transcrip-
tion [25–27]. To determine whether transactivation of pISRE-luc
by hMPV occurs via the canonical Jak/STAT pathway, we
investigated hMPV-induced ISRE-dependent gene transcription
in Jak1, Tyk2, STAT1, or STAT2 deficient cells, in comparison to
wild type cells. As shown in Fig. 1B, hMPV-infected 2fTGH cells
had about 4 fold higher ISRE-dependent gene transcription at 15
h p.i. than uninfected cells. However, hMPV failed to induce
luciferase activity in cells lacking STAT1, STAT2, Jak1, or Tyk2,
Figure 1. Induction of type I IFN signaling by hMPV infection.
(A) A549 cells were transfected with a luciferase reporter plasmid
containing five repeats of ISRE-binding sequence from ISG54 (pISRE-luc)
for 30 h. Cells were then mock infected, or infected with live or UV-
inactivated hMPV, at an MOI of 0.5, and harvested at various times p.i.
to measure luciferase activity. IFN-b (1000 units/ml) treatment was used
as a positive control. (B) Fibroblast cells 2fTGH and mutants lacking Jak1
(U4A), Tyk2 (U1A), STAT1 (U3A) or STAT2 (U6A) were transfected with
pISRE-Luc for 30 h, followed by mock infection or infection with hMPV,
at an MOI of 3, for 15 h. Cells were then lysed to measure luciferase
activity. (C) pISRE-luc-transfected 2fTGH and U3A cells were either mock
treated or treated with IFN-b for 15 h, followed by luciferase activity
measurement. In all experiments, luciferase was normalized to b-
galactosidase reporter activity. Data are representative of three
independent experiments and are expressed as mean 6 standard error
(SE) of normalized luciferase activity. *, P,0.05, relative to mock-
infected/treated cells.
doi:10.1371/journal.pone.0024496.g001
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necessary for hMPV-induced IFN-a/b signaling. IFN-b-treated
2fTGH cells showed a time-dependent increase in luciferase
activity, which started at 6 h p.i., peaked at 15 and declined by 24
h p.i. compared to untreated cells (data not shown), while
STAT1
2/2 cells did not response to IFN-b treatment (Fig. 1C),
confirming the response specificity of pISRE-Luc to IFN-b
simulation, and the importance of STAT1 in regulating IFN-b-
induced ISRE-dependent gene transcription.
IFN-b-mediated signal transduction is inhibited by hMPV
infection
Launching type I IFN signaling by virus infections is a critical
step to initiate the expression of anti-viral ISGs. Simultaneously
and progressively, viruses also develop strategies to counteract IFN
responses to evade host defense [28]. For example, infection of
RSV, a close family member to hMPV, increases baseline ISRE
promoter activity, but simultaneously suppresses IFN-b respon-
siveness of the ISRE by degrading STAT2 [29]. Recently, it was
reported that hMPV is also able to prevent IFN-a-mediated
signaling and subsequent induction of ISGs[24]. Consistent with
this observation, we also found that hMPV infection inhibited
IFN-b-dependent ISRE transactivation, as cells treated with both
hMPV and IFN-b did not have ISRE promoter activity equivalent
to additive levels of ISRE promoter activity induced by respective
treatment of hMPV and IFN-b (Fig. 2).
Several paramyxoviruses have been shown to inhibit type I IFN
signaling by interfering with STAT phosphorylation and stability
[30–32]. To determine the effect of hMPV infection on STAT1
and STAT2 activation in response to IFN-b treatment, A549 cells
were mock-infected or infected with hMPV, at an MOI of 0.5, for
6 or 15 h, followed by IFN-b stimulation for 1 h, time of maximal
STAT1 phosphorylation in response to the used concentration of
IFN-b treatment (data not shown). Cells were then harvested to
determine levels of STAT1 tyrosine phosphorylation. We found
that STAT1 phosphorylation was significantly induced in A549
cells in response to both IFN-b treatment alone and to hMPV
infection at 15 h p.i., with no changes in the amount of total
cellular STAT1 (Fig. 3A). Additional IFN-b treatment failed to
induce more STAT1 phosphorylation in cells infected with hMPV
for 15 h, compared to mock-infected IFN-b-treated cells, indicat-
ing that hMPV infection inhibits type I IFN-induced STAT1
phosphorylation, similar to what has been reported for RSV [29].
Because some paramyxoviruses are able to prevent type I IFN–
mediated signaling via by impairing STAT nuclear translocation
translocation is a key process for STAT1 [33,34], we investigated
the possibility that this mechanism contributes to the inhibition of
IFN-b-mediated signaling by hMPV. As shown in Fig. 3B, nuclear
levels of both phosphorylated and regular STAT1 were signifi-
cantly enhanced by IFN-b treatment or hMPV infection. At 6 h
p.i., IFN-b-induced STAT1 phosphorylation in the nuclear
compartment was not significantly affected by hMPV infection.
However, at 15 h p.i., cells infected and stimulated with IFN-b had
much less phosphorylated STAT1 than cells treated with IFN-b
alone (Fig. 3B, upper panel, lane 8 vs. lane 7 vs. lane 6). Total
nuclear STAT1 levels in response to IFN-b treatment were also
affected by hMPV infection, as cells receiving both treatments did
not exhibit an amount of STAT1 equivalent to additive levels
induced by hMPV infection and IFN-b stimulation alone (middle
panel: lane 4 vs lane 3+ lane 2, lane 8 vs lane 6+ lane 7). There was
no cytoplasmic protein contamination of the nuclear extracts, as
shown by the absence of b-tubulin in these samples (Fig. S1).
Western blot analysis was also used to determine whether
hMPV inhibition of IFN-b response involved changes in STAT2
activation. As shown in the upper panel of Fig. 3C, phosphory-
lated STAT2 was undetectable in mock-infected A549 cells, but
was markedly induced by IFN-b stimulation. In hMPV-infected
cells, STAT2 phosphorylation was detectable at 15 h p.i. In this
condition, IFN-b treatment of hMPV-infected cells did not result
in a further increase of STAT2 phosphorylation (lane 8 vs lane 7
and lane 6), suggesting that hMPV infection also affects IFN-b-
induced STAT2 activation. hMPV infection was associated with a
moderate increase in STAT2 levels, compared to mock-infected
cells, which is the opposite of what we observed in RSV-infected
cells, where there was significant STAT2 degradation (Fig. 3D),
consistent with what has been previously reported [29,35].
hMPV infection facilitates Jak1 and Tyk2 degradation
To determine whether the inhibitory effect of hMPV infection
on IFN-b-induced STAT activation was the result of a disruption
in the upstream cellular signaling pathway, we assessed protein
abundance of Jak1 and Tyk2 in response to hMPV infection and/
or IFN-b treatment. Western blot analysis revealed that Jak1 and
Tyk2 cellular abundance was markedly reduced in response to
hMPV infection itself, and in cells infected and treated with IFN-b,
suggesting that inhibition of IFN-b-induced STAT1 and STAT2
phosphorylation results from hMPV-induced degradation of these
two molecules (Fig. 4A). In Vero cells, which lack genes encoding
type I IFNs, hMPV infection also induced Jak1 and Tyk2
degradation (Fig. 4B), indicating that this effect is directly induced
by the virus and is not IFN-b-dependent.
In contrast, abundance of Jak1 and Tyk2 was not changed by
RSV infection (Fig. 4C), indicating that RSV and hMPV use
different mechanisms to impair type I IFN signaling.
hMPV-induced Jak1 and Tyk2 degradation is
proteasome-dependent
Proteasome-dependent degradation of Jak/STAT pathway
components has been shown to be an important mechanism for
paramyxovirus evasion of host responses. For example, human
parainfluenza virus type 2 and RSV both induce downregulation
of STAT2 levels via a proteasome-dependent pathway [36,37]. To
Figure 2. IFN-b-dependent signaling is inhibited by hMPV
infection. A549 cells were mock- or hMPV-infected at an MOI of 0.5 for
24 h, and then transfected with pISRE-luc, followed by mock- or IFN-b
treatment for an additional 15 h. For each plate luciferase was
normalized to b-galactosidase reporter activity. Data are representative
of two independent experiments and are expressed as mean 6 SE of
normalized luciferase activity.
doi:10.1371/journal.pone.0024496.g002
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and then mock- or IFN-b-treatment for one additional hour. Total cells were harvested, followed by Western blot to determine the abundance of
phosphorylated and non-phosphorylated STAT1. Membranes were stripped and reprobed for b-actin to document equal loading of the samples.
Expression ratio of pSTAT1/STAT1 was normalized to b-actin. (B) A549 cells were infected with hMPV and/or treated with IFN-b as described in A.
Nuclear fractions were prepared followed by Western blot using anti phospho-STAT1 (p-STAT1) and STAT1 antibodies. Membranes were stripped and
reprobed for lamin B, as loading control. The nuclear translocated ratio of pSTAT1/STAT1 was normalized to lamin B. (C) Total cell lysate were
prepared as described in A, followed by Western blot to determine the abundance of phosphorylated and non-phosphorylated STAT2. Membranes
were stripped and reprobed for b-actin as a control for equal loading of the samples. Expression ratio of pSTAT2/STAT2 was normalized to b-actin. (D)
A459 cell were mock- or RSV- infected, at an MOI of 0.5, for 6 or 15 h, and then mock- or IFN-b-treated for one additional hour. Total cell lysates were
prepared, followed by Western blot to determine the abundance of phosphorylated and total STAT2. Membranes were stripped and reprobed for b-
actin. STAT2 expression was normalized to b-actin. For (A), (B) and (C), *, P,0.05, relative to mock-infected and IFN-b-treated treated cells at 15 h. For
(D), *, P,0.05, relative to mock-infected cells at 15 h p.i., according to their respective IFN-b treatment condition. The results are representative of two
to three separate experiments. Densitometric analysis of Western blot band intensities was performed using VisionWorksLS image acquisition and
analysis software from UVP (Upland, CA). Data are presented as mean 6 SE of arbitrary units.
doi:10.1371/journal.pone.0024496.g003
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permeable, nonspecific proteasome inhibitor MG-132 or the
proteasome specific inhibitor lactacystin [38,39], infected with
hMPV, and harvested to measure Jak1 and Tyk2 levels in treated
versus untreated cells by Western blot. We found that hMPV
infection failed to reduce Jak1 and Tyk2 levels in A549 cells
pretreated with 5 mM of MG132 or 10 mM of lactacystin (Fig. 5A
and B). Because MG132 treatment has been previously shown to
affect viral replication [40,41], we examinated levels of hMPV
protein synthesis in infected cells treated with MG132 by Western
blot. There was no significant difference in hMPV protein
expression in infected cells in the presence or absence of MG132
treatment, indicating that inhibition of Jak1 and Tyk2 degradation
was not due to changes in viral replication (Fig. 5A).
In addition, hMPV infection also affected Jak1 and Tyk2 gene
expression, as shown by a progressive decrease in Jak1 and Tyk2
mRNA levels in viral-infected cells (Fig. 5C), while there were no
changes in Jak1 and Tyk2 expression in response to RSV infection
(data not shown). On the other hand, STAT1, STAT2, IFNRA1,
or IFNRA2 mRNA levels were unaffected by hMPV infection
(data not shown).
Function of the ubiquitin-proteasome pathway is essential for
many fundamental cellular processes, including the regulation of
signaling pathways in the context of viral infections [42]. It has
been previously shown that RSV degrades STAT2 by using the
Elongin-Cullin E3 ligase, which is a ubiquitin ligase (E3) enzyme
[35]. Therefore, we investigated whether hMPV degraded Jak-1
and Tyk-2 in an ubiquitin-proteasome-dependent pathway. A549
cells were mock infected or infected with hMPV for 6 h in the
presence or absence of 5 mM of MG132. Total cell lysates were
immunoprecipitated by an anti- polyubiquitin antibody (Santa
Cruz, Biotechnology, Santa Cruz, CA), followed by Western blot
using anti-Jak1 or anti-Tyk2 antibodies (Cell Signaling). We found
that hMPV-infected cells had more ubiquitinated Jak1 and Tyk2
than mock-infected cells (Fig. 5D), suggesting the involvement of
an ubiquitin-proteasome pathway in the degradation of Jak1 and
Tyk2 in the context of hMPV infection.
hMPV infection modulates the surface expression of
IFNAR1 subunits
Since some viral infections have been shown to reduce cell
surface expression of IFN receptors, as a mechanism to disrupt
IFN-dependent signaling [43,44], we investigated whether hMPV
infection resulted in changes of IFNAR1 cell surface levels by
using flow cytometry analysis of A549 and Vero cells. Compared
to mock-infected cells, viral-infected A549 cells showed a time-
and dose-dependent reduction of surface IFNAR1 expression
(Fig. 6A). In contrast, surface expression of major histocompati-
bility complex-I (MHC-I) was either not changed at 6 h p.i., or
considerably increased at 15 h p.i. (data not shown), suggesting
that the decrease in IFNAR1 expression was unlikely due to
altered cell viability. IFN-b treatment per se affected surface
IFNAR1 expression in A549 cells (Fig. 6B), suggesting that hMPV-
induced IFN-b secretion might contribute to reduced IFNAR1
surface levels. However, hMPV infection also reduced IFNAR1
surface expression in Vero cells, although to a less extent (data not
shown), indicating that there is a ligand-independent pathway
contributing to the suppression of IFNAR1 surface expression.
Western blot analysis revealed that the amount of IFNAR1 in total
Figure 4. hMPV infection affects cellular levels of Jak1 and
Tyk2. A549 cells (A) or Vero cells (B) were mock- or hMPV-infected, at
an MOI of 0.5, for 6 or 15 h, followed by mock or IFN-b treatment for
1 h. Cells were harvested to prepare total cell lysates. Abundance of
total Jak1 and Tyk2 was analyzed by Western blot, followed by
densitometric analysis of Western blot band intensities using Vision-
WorksLS image acquisition and analysis software from UVP (Upland,
CA). The band intensities were then normalized to b-actin levels. Data
are representative of two to three independent experiments and are
expressed as mean 6 SE of normalized gene expression.*, P,0.05,
relative to mock-infected cells, according to their respective IFN-b
treatment condition and time point of p.i. (C) A549 cells were mock- or
RSV-infected, at an MOI of 0.5, for 6 or 15 h, followed by mock or IFN-b
treatment for 1 h. Cells were harvested to prepare total cell lysates.
Abundance of total Jak1 and Tyk2 was analyzed as described in A and B.
Data are representative of two to three independent experiments.
doi:10.1371/journal.pone.0024496.g004
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cells (Fig. 6C), indicating that hMPV infection facilitated the
internalization, but not degradation of IFNAR1.
Impaired IFN-b response following hMPV infection is
replication-dependent
To examine the importance of viral replication on regulation of
IFN-b-activated Jak/STAT pathway, STAT1 phosphorylation
and the abundance of Jak1/Tyk2 were compared in A549 cells
infected with live and UV-inactivated hMPV. Consistent with
previous findings, phosphorylated STAT1 was undetectable in
mock-infected A549 cells, but was readily detectable 1 h after IFN-
b treatment. Infection with replicating, but not UV-inactivated
virus, reduced IFN-b-induced STAT1 phosphorylation (Fig. 7).
Similarly, infection with live, but not UV-inactivated virus, led to
significant reduction of Jak1 and Tyk2 cellular levels (Fig. 7),
indicating that inhibition of Jak/STAT pathway is dependent on
viral replication and gene transcription, which is lost upon UV
irradiation.
Taken together, these results indicate that hMPV modulates
type I IFN-dependent Jak/STAT pathway by inducing protea-
some-dependent degradation of Jak1 and Tyk2 and reducing
surface expression of IFNAR1, ultimately leading to inhibition of
STAT1 and STAT2 activation.
Discussion
Epithelial cells are the primary target for respiratory virus
infection. They actively participate in anti-viral responses by
releasing and responding to type I IFNs. Previously, we showed
that airway infection with hMPV resulted in the release of type I
IFNs, IFN-a and IFN-b, both in vitro and in vivo [13,45]. The
secreted IFN-a/b likely binds to its receptors on cell surface,
leading to the induction of gene transcription of anti-viral ISGs
(Fig. 1A).
In the face of IFN-dependent host anti-viral defense strategies,
many viruses simultaneously launch several counter mechanisms,
which include inhibiting IFN synthesis, affecting type I IFN
responses, and blocking expression of ISGs [46,47]. We have
recently shown that recombinant hMPV lacking glycoprotein G
induces more type I IFN than its wild type counterpart,
demonstrating the G protein of hMPV is inhibitory for viral-
induced type I IFN synthesis [48]. In this study, we further
Figure 5. hMPV-induced Jak1 and Tyk2 degradation is proteasome-dependent. A549 cells were pretreated with 1 or 5 mM MG132 (A) or
10 mM lactacystin (B) for 1 h. Untreated cells were used as a control. After treatment, cells were mock-infected or infected with hMPV for 15 h and
harvested to prepare total cell lysates. Jak1 and Tyk2 abundance was analyzed by Western blot. Membranes were also probed with anti-hMPV
antibody to evaluate the effects of MG132 on viral replication. Membranes were stripped and reprobed with b-actin as a control for equal loading of
the samples. *, P,0.05, relative to mock-infected cells, according to their respective MG132/lactacystin treatment conditions. (C) Total RNA was
extracted from uninfected or infected A549 cells at 6, 15, and 24 h p.i., and used for Q-RT-PCR to determine changes in Jak1 and Tyk2 gene
expression. 18S RNA was used as an internal control for normalization. Data are presented as fold changes of Jak1/Tyk2 mRNA levels in hMPV-infected
cells compared to mock-infected. *, P,0.05, relative to mock-infected cells. (D) A549 cells were mock-infected or infected with hMPV in the presence
of 5 mM MG132 for 6 h and harvested to prepare total cell lysate. Small aliquots were saved for Jak1 and Tyk2 abundance analysis by Western blot.
Membranes were stripped and reprobed with b-actin as a control for equal loading of the samples. The rest of the samples were immunoprecipitated
using an anti-polyubiquitin antibody, followed by Western blot using anti-Jak1 or anti-Tyk2 antibody. For all the experiments, data are representative
of two to three independent experiments and are expressed as mean 6 SE of normalized gene transcription or translation.
doi:10.1371/journal.pone.0024496.g005
hMPV and Type I IFN Response
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signaling, leading to inhibition of IFN-b signaling transduction
(Fig. 2). The inhibitory effect of hMPV on type I IFN signaling
occurs at different levels of the signaling cascade, as the virus
partially blocks Jak1 and Tyk2 gene transcription, facilitates Jak1
and Tyk2 degradation, and lowers IFNAR1 membrane expres-
sion, ultimately leading to inhibition of STAT1 and STAT2
activation. It has been shown that RSV, another important
mucosal respiratory virus sharing similar clinical symptoms with
hMPV, also inhibits type I IFN signaling in airway epithelial cells.
However, the inhibition mechanisms employed by these two
viruses are different. RSV seems only induce the downregulation
of STAT2 without affecting Jak1 and Tyk2 (Fig. 4C). Unlike Jak1,
which plays a significant role in mediating both type I and II IFN
signaling, STAT2 only controls type I IFN signaling. Therefore,
the selective degradation of STAT2 by RSV might account for its
selective inhibition on type I IFN signaling in airway epithelial cells
[49].
Other paramyxoviruses have also evolved a variety of strategies
to counteract the antiviral effects of IFNs [50]. The V proteins of
simian virus 5 (SV5) and human parainfluenza virus 2 (HPIV2)
(genus Rubulavirus) are able to target STAT1 and STAT2 for
polyubiquitination and proteasomal degradation [30,31]. V
proteins of Henipavirus and Nipah viruses, on the other hand,
sequester STAT1 and STAT2 in high molecular mass cytoplasmic
complexes without inducing their degradation. The C protein of
Sendai virus disrupts IFN-signaling via inhibiting STAT1 and
STAT2 tyrosine phosphorylation, while the V and C proteins of
measles virus inhibit Jak1 phosphorylation and dissociate Jak
proteins from the signaling complex [32]. Therefore, it is
reasonable to hypothesize that hMPV encodes one or more
proteins that are responsible for the inhibitory effects on type I
IFN signaling. Currently, we are attempting to identify the viral
components that are responsible for inhibition of type I IFN
signaling.
In this study, we found that hMPV downregulates the
expression of Jak1 and Tyk2 in infected airway epithelial cells as
early as 6 h p.i. Infection with hMPV also reduces the expression
of Jak1 and Tyk2 in Vero cells. Given the fact that Vero cells do
not produce IFN-b, this result suggests that downregulation of
Jak1 and Tyk2 by hMPV infection is probably independent of type
I IFN. We also found that UV-inactivated hMPV is not able to
inhibit the expression of Jak1 and Tyk2, suggesting that de novo
viral gene expression and/or viral RNA replication is required for
inhibition of expression of Jak1 and Tyk2. Although the global
shutoff of host macromolecular synthesis plays an important role
in pathogenesis of some viruses [51], our data suggest that this is
not required for hMPV-mediated inhibition of Jak/STAT
signaling, because reduced protein expression of Jak1 and Tyk2,
and inhibition of STAT1 phosphorylation were not associated
with an effect of hMPV on total STAT1 abundance. As hMPV-
induced Jak1/Tyk2 degradation is proteasome-dependent, it is
possible that a particular viral protein binds to specific host targets,
facilitating the delivery of these targets to the proteasome, similar
to what has been shown for RSV NS1 protein, that has the
capacity to assemble ubiquitin ligase E3 enzymes to specifically
target STAT2 for proteasome [35]. In addition to proteasome-
dependent degradation, inhibition of mRNA transcription, by a
yet to be identified mechanism, during the course of hMPV
infection may also account for reduced expression of Jak1 and
Tyk2.
In this study, we also detected reduced IFNAR1 surface
expression in hMPV-infected airway epithelial cells, which
occurred as early as 6 h p.i. Both reduced surface expression of
IFNAR and downregulation of Jak1 and Tyk2 might contribute to
reduced phosphorylation of STAT1 and STAT2, leading to
inhibition of type I IFN responses. Both A549 and Vero cells had
lower surface expression of IFNAR1 following hMPV infection,
while the total cellular abundance of IFNAR1 was comparable in
mock- and hMPV-infected cells (Fig. 6C). Tyk2-null cells have
reduced surface levels of IFNAR1 protein, and as a consequence,
binding of IFN-a is severely reduced. Conversely, when com-
plexed to Tyk2, IFNAR1 is stabilized on the plasma membrane
[52,53]. Therefore, our results suggest that increased internaliza-
tion of IFNAR1 following hMPV infection might result from the
degradation of Tyk2, which is ligand-independent. This conclu-
sion is also supported by the fact that RSV, which does not
facilitate Tyk2 degradation, did not induce internalization of
IFNAR1 in Vero cells (data not shown). Ligand-dependent
pathway may also contribute to IFNAR1 internalization, as
IFN-b treated A549 cells also had lower surface IFNAR1
expression than untreated cells (Fig. 6B), and hMPV- induced
IFNAR1 internalization in Vero cells was not as significant as that
in A549 cells (data not shown).
In summary, these studies demonstrate that hMPV antagonizes
type I IFN responses through mechanisms involving the regulation
of STAT1, STAT2, Jak1, Tyk2, and surface expression of
IFNAR1. Whether inhibition of type I IFN responses represents
an individual event or a series of sequential events following
infection needs to be further investigated. In addition, whether or
not the inhibition of type I IFN signaling by hMPV plays a role in
pathogenesis and severity of infection also needs to be investigated,
as inhibition of IFN signaling may affect development of host
adaptive immunity, leaving the host susceptible to reinfection [54].
Therefore, a better understanding of how hMPV inhibits the type
I IFN pathway, and its consequences with regard to the innate and
adaptive immune responses, is crucial for improving therapeutic
approaches and the development of better vaccines against hMPV
infection.
Materials and Methods
Cell culture and viral infection
All media for cell culture was from GIBCO (Invitrogen,
Carlsbad, CA) and supplemented with 100 IU/ml penicillin and
100 mg/ml streptomycin. A549, human alveolar type II-like
Figure 6. Surface expression of IFNAR1 subunits is reduced in hMPV-infected cells. (A) A549 cells were mock-infected or infected with
hMPV at an MOI of 0.1 or 0.5, for 6 or 15 h. Cells were either stained with anti-IFNAR1 and isotype control antibody. After 1 h incubation at 37uC, cells
were washed with PBS containing 5% FBS, followed by another incubation with anti-mouse FITC-conjugated secondary antibody at 37uC. (B) A549
cells were stimulated with 1,000 U/ml of IFN-b for various periods of time as indicated. Antibody staining was done as described in (A). Samples were
analyzed on a FACSCAN flow cytometer equipped with BD FACSDiva software. Analysis was performed using FlowJo software (version 7.2.2; Tree Star
Ashland, OR). % of IFNRA positive cells of mock- and hMPV-infected samples was compared. *, P,0.05, relative to mock-infected and IFNRA antibody-
stained cells. Data are representative of two to three independent experiments, and are expressed as mean 6 SE of IFNRA surface expression. (C)
A549 cells were mock- or hMPV-infected, at an MOI of 0.1 or 0.5, for 15 h, and harvested to prepare total cell lysates. IFNAR1 abundance was
determined by Western blot. Membranes were stripped and reprobed for b-actin as a control for equal loading of the samples. Data are
representative of two to three independent experiments.
doi:10.1371/journal.pone.0024496.g006
hMPV and Type I IFN Response
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24496epithelial cells (ATCC, Manassas, VA), were maintained in F12K
medium containing 10% (v/v) FBS. Monkey kidney Vero and
LLC-MK2 cells (ATCC, Manassas, VA) were maintained in
MEM supplemented with 5% and 10% fetal bovine serum,
respectively. The fibroblast cell line, 2fTGH, and mutants of
2fTGH lacking Jak1, Tyk2, STAT1 or STAT2 were generously
provided by Dr. George R. Stark (Cleveland Clinic, Cleveland,
Ohio) and cultured in DMEM supplemented with 1% sodium
pyruvate and 1% hygromycin B.
Virus preparation and viral infection
The Canadian isolate hMPV83 was propagated in LLC-MK2
cells at 37uC in the absence of serum and in the presence of 1 mgo f
trypsin/ml (Worthington, Lakewood, NJ). Viruses were purified by
sucrose gradient centrifugation, as previously described [45,48].
Viral titer was determined by immunostaining in LLC-MK2 cells,
as previously described [48,55]. Cell monolayers were infected
with hMPV at a multiplicity of infection (MOI) of 0.5 in serum-
free medium containing antibiotics and 1 mg trypsin/ml for all
experiments, unless otherwise stated. Cells treated with infection
media plus sucrose were defined as mock-infected.
Reporter gene assays
Reporter gene assays were used to assess STAT-dependent gene
transcription. A luciferase reporter plasmid (pISRE-Luc, Strata-
gene, La Jolla, CA) containing direct repeats of the interferon-
stimulated response element (ISRE) found in the promoter of the
54-kDa interferon-stimulated gene 54 (ISG54) was transfected into
log phase A549 cells or fibroblasts in triplicate using FuGene 6
(Roche, Basel, Switzerland), as previously described [56–59]. The
next day, cells were infected with hMPV at an MOI of 0.5 for
various times as indicated, or treated with IFN-b as positive
controls. Plates containing uninfected cells served as negative
controls. Cells were lysed and luciferase and b-galactosidase
reporter activities were independently measured, as previously
described [60]. All experiments were performed in duplicate or
triplicate. In experiments investigating the role of hMPV in
modulating the IFN-b response, cells were first infected with
hMPV at an MOI of 0.1 for 24 h and then transfected with 2 mg
of pISRE-Luc. Medium was removed 15 h after transfection and
replaced with FBS-free medium containing IFN-b (1,000 IU/ml).
After a 6 h incubation, luciferase levels from lysed cells were
measured as previously described [60].
Cellular and nuclear extracts
A549 cells were mock infected or infected with hMPV for 6 or
15 h, and then treated with 1000 units/ml of IFN-b for 1 h. Total
cell lysates were then prepared by adding ice-cold lysis buffer
(50 mM Tric-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 0.25%
sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1% Triton X-
100 and 1 mg/ml aprotinin, leupeptin and pepstatin). After
incubation on ice for 10 min, the lysates were collected and
detergent insoluble materials were removed by centrifugation at
4uC at 14,000 g. To investigate nuclear translocation of STATs,
nuclear extracts from the cells were prepared using hypotonic/
nonionic detergent lysis, according to the Schaffner protocol [61].
To prevent contamination with cytoplasmic proteins, isolated
nuclei were purified by centrifugation through 1.7 M sucrose
buffer A for 30 min, at 14,000 g before nuclear protein extraction,
as previously described [62]. Cellular and nuclear extracts were
then quantified using BCA Protein Assay Kit from Thermo Fisher
Scientific (Thermo Fisher Scientific, Waltham, MA).
Western blot analysis
Nuclear extracts or total cell lysates were fractionated by SDS-
PAGE, and transferred to polyvinylidene difluoride membranes.
Membranes were blocked with 5% milk, 0.5% Tween-20 in Tris
Figure 7. Inhibition of Jak/STAT1 signaling pathway is virus
replication dependent. (A) A549 cells were mock-infected or
infected with live hMPV or UV-inactivated hMPV for 15 h. Cells were
then treated with medium or 500 U/ml of IFN-b for 1 h. Abundance of
phosphorylated and total STAT1, Jak1 and Tyk2 in total cell lysates was
then analyzed by Western blot. Membranes were stripped and
reprobed with b-actin as a control for equal loading of the samples.
(B) Densitometric analysis for A. densitometric analysis of band
intensities was performed using VisionWorksLS Image Acquisition and
Analysis Software from UVP (Upland, CA) according to the manufac-
turer’s instruction. Data are representative of three independent
experiments, and are expressed as mean 6 SE of protein expression.
*, P,0.05, relative to mock-infected cells, according to their respective
IFN-b treatment conditions.
doi:10.1371/journal.pone.0024496.g007
hMPV and Type I IFN Response
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24496buffered saline (TBS), and incubated with the proper primary
antibodies according to the manufacturer’s instruction. Primary
antibodies for detection of p-Jak1 (Y1022/1023), Jak1, p-Tyk2
(Y1054/1055), Tyk2, p-STAT1 (Y701), STAT1, p-STAT2
(Y690), and STAT2 were from Cell Signaling (Cell Signaling
Technology, Inc, Danvers, MA). Primary antibodies against
IFNAR1 and anti-total ubiquitin were purchased from Santa
Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). Primary
antibody against hMPV was a gift from Medimmune (Medim-
mune, Mountain View, CA). Appropriate horseradish peroxidase-
coupled secondary antibody was then used and proteins were
detected by enhanced chemiluminescence assay (Amersham,
Piscataway, NJ). Equal loading of proteins was evaluated by
stripping and reprobing the membranes with anti-b actin or anti-
lamin B antibodies.
Quantitative real-time PCR analysis
A549 cells were either mock infected or infected with hMPV at
an MOI of 1. At the indicated time points, total RNA was isolated
using Trizol (Invitrogen, Carlsbad, CA). Synthesis of cDNA was
performed using 1 mg total RNA in a 20 ml reaction using the
reagents in the Taqman Reverse Transcription Reagents Kit,
Applied Biosystems, Inc. (ABI), Foster City, CA). Q-PCR
amplifications (performed in triplicate) were done using 2 ml
cDNA in a total volume of 25 ml containing SYBR Green PCR
Master Mix (ABI, Foster City, CA) as specified by the
manufacturer. The final concentration of the paired primers was
900 nM. Sequence information is available upon request. Real-
time PCR was performed in an ABI 7500 thermocycler. Triplicate
cycle threshold (CT) values were analyzed by the comparative ABI
CT (DDCT) method. The relative amount of transcribed mRNA
was normalized relative to the level of endogenous 18s RNA from
each individual sample.
Flow cytometry
To determine the relative IFNAR1 surface expression, conflu-
ent A549 cells or Vero cells were infected with hMPV or mock
treated for 6 or 15 h. Cells were detached from the culture plate
using Accutase
TM enzyme cell detachment medium (eBioscience,
San Diego, CA), and then washed twice with ice-cold wash
solution (PBS with 5% heat-inactivated FCS). Cells were then
incubated with mouse anti-IFNAR1 Abs (PBL, Piscataway, NJ) for
30 min. followed by staining using a FITC goat anti-mouse
secondary antibody for another 30 min. Cells were then washed
and fixed in 1% paraformaldehyde. In a separate set of
experiments, A549 cells were stained with anti-MHC I antibodies
to indirectly verify cell viability. Samples were analyzed using
FACScan flow cytometer equipped with CellQuest software (both
from Becton Dickinson Immunocytometry Systems, San Jose,
CA). Analysis was performed in Flowjo software (Tree star, La
Jolla, CA). Relevant isotype control antibodies were used for the
mean intensity correction.
Statistical Analysis
Statistical significance was analyzed using analysis of variance
(ANOVA). P value of less than 0.05 was considered significant.
Mean 6 standard error (SE) is shown.
Supporting Information
Figure S1 A549 cells were mock- or hMPV-infected at an MOI
of 0.5, for 6 or 15 h, and then mock- or IFN-b-treated for one
additional hour. Cells were harvested to prepare nuclear extract,
which were probed by Western blot for-b-tubulin content, to
exclude cytoplasmic protein contamination. A cytoplamic sample
(cyto) from mock-infected cell was used as a positive control.
(TIF)
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